AUPH · Aurinia Pharmaceuticals Inc
United States · RS rating 78 · As of 2026-11-03
| Price | 16.56 USD |
|---|---|
| 1-day change | +2.6% |
| RS rating (overall / 1M / 3M / 12M) | 78 / 72 / 81 / 72 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 44 / 35 / 65 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +565.2% |
| Sales growth Q/Q | +5.0% |
| Distance from 52-week high | +11.1% |
| Market cap (USD) | $2.1B |